Why the study?
External quality assessment surveys report high inter-assay variability in anti-FXa assays for monitoring UFH and LMWH, requiring optimization to measure all circulating drug activity.
Does the use of dextran sulfate and CTAD anticoagulant improve the accuracy of anti-FXa assays for monitoring heparin activity in patient plasma?
Does the use of dextran sulfate and CTAD anticoagulant improve the accuracy of anti-FXa assays for monitoring heparin activity in patient plasma?
The addition of low molecular weight dextran sulfate and the use of CTAD anticoagulant are crucial for accurate and comparable monitoring of heparin activity using anti-FXa assays.
No takes yet. Share an insight, caveat, or question.
Should not yet change heparin monitoring practice; hypothesis-generating for dextran sulfate-enhanced anti-FXa assay accuracy.
Amiral et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: